1052720-28-1Relevant articles and documents
Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia
Deshpande, Anil M.,Bhuniya, Debnath,De, Siddhartha,Dave, Bhavesh,Vyavahare, Vinod P.,Kurhade, Santosh H.,Kandalkar, Sachin R.,Naik, Keshav P.,Kobal, Balasaheb S.,Kaduskar, Rahul D.,Basu, Sujay,Jain, Vaibhav,Patil, Pratima,Chaturvedi Joshi, Sandhya,Bhat, Ganesh,Raje, Amol A.,Reddy, Satyanarayana,Gundu, Jayasagar,Madgula, Vamsi,Tambe, Suhas,Shitole, Prasad,Umrani, Dhananjay,Chugh, Anita,Palle, Venkata P.,Mookhtiar, Kasim A.
, p. 268 - 286 (2017/04/13)
Glucokinase activators (GKAs) are among the emerging drug candidates for the treatment of type 2 diabetes (T2D). Despite effective blood glucose lowering in clinical trials, many pan-GKAs “acting both in pancreas and liver” have been discontinued from cli
